#cancer research

Engineered immune cells get a helping hand in a new clinical trial for multiple myeloma patients.

A $35 million gift from Marc and Lynne Benioff will accelerate research to transform prostate cancer treatment.

The team reasoned that if reducing DNA repair killed some cells, then a dramatically reducing DNA repair could kill even more.

By combining the tools of pathology, computational modeling and genomics, the project hopes to discover and test therapeutic interventions.

For clinical oncologists, cancer researchers, and leaders in health technology who want to be at the forefront of conquering cancer.

SPORE grants have become the cornerstone of NCI’s efforts to advance collaborative, interdisciplinary translational cancer research.

When Dana-Farber’s Catherine Wu, MD, was a newly minted physician in the mid-90s, there was just one major form of immunotherapy for cancer.

Forty-five percent of 182 phase 3 clinical trials between 1980 and 2017 influenced guideline care or new drug approvals.

Surprising new research suggests why 97% of cancer drugs in clinical trials fail to stop cancer in patients and never make it to market.

The combination of chemoimmunotherapy with a targeted drug represents a step toward a new standard of care for people with CLL.

Yung S. Lie, PhD, is the president and CEO of the Damon Runyon Cancer Research Foundation.

At her lowest ebb, breast cancer survivor Amanda Enayati, our cover subject, discovered serenity.

Prestigious prize goes to researchers who identified B cells and T cells and others who invented the HER2 targeted cancer therapy Herceptin.

Yung S. Lie, PhD, sat down with Denver Frederick, host of “The Business of Giving,” to discuss the history and strategy of the organizatio...

Breast cells are deprived of a particular type of DNA damage repair, causing normals cells to change to a pre-malignant state.

“We can speculate that there’s going to be all kinds of interesting nutritional interventions that could influence cancer.”